Reactions 1704, p35 - 2 Jun 2018 Depressed level of consciousness and renal disorders: 4 case reports In a prospective, multi-centre, observational study (EURO- B.O.S.S.) of 218 patients, four patients (including a female patient) [ages not stated; not all sexes stated] were described. One patient developed grade 4 depressed level of consciousness following treatment with ifosfamide, and another patient developed grade 4 renal toxicity while receiving doxorubicin, cisplatin and ifosfamide. The two remaining patients developed delayed methotrexate excretion associated with grade 3 nephrotoxicity or grade 1 creatinine elevation following the administration of methotrexate 8 g/m infusion [durations of treatments to reaction onsets not stated; not all routes, dosages and outcomes stated]. All patients were receiving the chemotherapies for primary high grade bone sarcoma. The female patient, who developed grade 4 renal toxicity, underwent dialysis and her renal function had normalised. Author comment: "The EURO-B.O.S.S. treatment concept led to results that seem comparable to those also achieved in younger patients with primary high-grade osteosarcoma, albeit at the cost of relevant side effects." Ferrari S, et al. EURO-B.O.S.S.: A European study on chemotherapy in bone- sarcoma patients aged over 40: Outcome in primary high-grade osteosarcoma. Tumori 104: 30-36, No. 1, Jan-Feb 2018. Available from: URL: http:// doi.org/10.5301/tj.5000696 - Italy 803323787 0114-9954/18/1704-0001/$14.95 Adis © 2018 Springer International Publishing AG. All rights reserved Reactions 2 Jun 2018 No. 1704
Reactions Weekly – Springer Journals
Published: Jun 2, 2018
It’s your single place to instantly
discover and read the research
that matters to you.
Enjoy affordable access to
over 18 million articles from more than
15,000 peer-reviewed journals.
All for just $49/month
Query the DeepDyve database, plus search all of PubMed and Google Scholar seamlessly
Save any article or search result from DeepDyve, PubMed, and Google Scholar... all in one place.
Get unlimited, online access to over 18 million full-text articles from more than 15,000 scientific journals.
Read from thousands of the leading scholarly journals from SpringerNature, Elsevier, Wiley-Blackwell, Oxford University Press and more.
All the latest content is available, no embargo periods.
“Hi guys, I cannot tell you how much I love this resource. Incredible. I really believe you've hit the nail on the head with this site in regards to solving the research-purchase issue.”Daniel C.
“Whoa! It’s like Spotify but for academic articles.”@Phil_Robichaud
“I must say, @deepdyve is a fabulous solution to the independent researcher's problem of #access to #information.”@deepthiw
“My last article couldn't be possible without the platform @deepdyve that makes journal papers cheaper.”@JoseServera